Mebendazole Is a Potential Alternative in the Treatment of Giardia duodenalis Infection

Cañete, Roberto

doi:10.1016/j.curtheres.2016.03.001

Cited by 2 publications

(2 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For decades, 5-nitroimidazole compounds have been the treatment of choice for giardiasis and are still widely used. However, reports of infections refractory to treatment with these compounds are becoming more common and have stimulated the search for alternative treatment options 5, 18. Other clinical situations, such as postinfection lactose intolerance or reinfections, explain why treatment of G. duodenalis continues to be challenging and why not all patients treated with the standard, recommended therapies are cured 5 …”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials

Cañete¹,

Brito

et al. 2018

Current Therapeutic Research

Self Cite

View full text Add to dashboard Cite

BackgroundGiardia duodenalis is the most common intestinal pathogenic protozoan infection reported in humans. Both in vitro studies and 4 separate, sequential, comparative clinical trials conducted by our group in Cuba demonstrated mebendazole activity against G. duodenalis infection in both children and adults.ObjectiveThe 2 additional, prospective, open-label, Phase IV follow-up studies reported here were performed to further assess the effectiveness and safety profile of mebendazole in the outpatient treatment of G. duodenalis infection.MethodsAssenting children (n = 522) whose guardians gave permission and consenting adults (n = 423) diagnosed with G. duodenalis infection were given mebendazole (200 mg 3 times daily for 3 days). Medical histories and stool samples were obtained and physical/laboratory examinations were performed pretreatment then repeated on days 3, 5, and 7 after treatment completion. The evaluation of efficacy (ie, cure) was based on parasitologic response to therapy. Participants were considered cured, if no Giardia trophozoites or cysts were found in any of the 3 posttreatment fecal specimens evaluated by direct wet mounts and/or after Ritchie concentration techniques.ResultsNo participant refused to be enrolled and all returned for follow-up examinations. At the end of the treatment, stool samples were negative in 450 out of 522 children (86.2%) and 392 of 423 adults (92.7%). Treatment was well tolerated. In adults, the only adverse effect reported was abdominal pain (6.2%). Side effects reported in children included abdominal pain (5.6%), nausea (2.9%), and vomiting (2.3%). Reported side effects were all mild, transient, and self-limited and did not require discontinuation of treatment or additional medication.ConclusionsMebendazole may be an effective alternative treatment of G. duodenalis infections in both children and adults.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials

Cañete¹,

Brito

et al. 2018

Current Therapeutic Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…The mechanism by which MBZ inhibits tumor growth is due in part to the inhibition of glucose uptake and glycolytic enzymes (34,35). MBZ has relatively low toxicity in both adults and in children (36)(37)(38). As systemic bioavailability is best when MBZ is administered orally with fatty foods (39,40), we administered MBZ with a ketogenic diet to young mice with invasive VM-M3 glioma in this study.…”

Section: Introductionmentioning

confidence: 99%

Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma

Mukherjee

Greenwood²,

Henao³

et al. 2023

Preprint

View full text Add to dashboard Cite

Invasion of high-grade glioma (HGG) cells through the brain and spinal cord is a leading cause of cancer death in children. Despite advances in treatment, survivors often suffer from life-long adverse effects of the toxic therapies. This study investigated the influence of nutritional ketosis on the therapeutic action of mebendazole (MBZ) and devimistat (CPI-613) against the highly invasive VM-M3 glioblastoma cells in juvenile syngeneic p20-p25 mice; a preclinical model of pediatric HGG. Cerebral implantation of the VM-M3 glioblastoma cells invaded throughout the brain and the spinal column similar to that seen commonly in children with malignant glioma. The maximum therapeutic benefit of MBZ and CPI-613 on tumour invasion and mouse survival occurred only when the drugs were administered together with a ketogenic diet (KD). MBZ reduced VM-M3 tumour cell growth and invasion when evaluated under in-vitro and in-vivo conditions through inhibition of both the glutaminolysis and the glycolysis pathways. Moreover, administration of the drugs with the KD allowed lower dosing of the juvenile mice, which minimized toxicity while improving overall survival. This preclinical study in juvenile mice highlights the potential importance of a diet/drug therapeutic strategy for managing childhood brain cancer.

show abstract

Mebendazole Is a Potential Alternative in the Treatment of Giardia duodenalis Infection

Cited by 2 publications

References 10 publications

Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials

Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials

Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma

Contact Info

Product

Resources

About